Role of thoracostomy in the management of postoperative empyema following lung resection: a narrative review of surgical strategies, evolving techniques, and outcomes Authors: Alexey A. Pechetov, Dmitrii A. Volchanskii, Pavel V. Kononets, Vladislav E. Bugaev, Andrei I. Gritsiuta Published: 2026 ABSTRACT Background and ObjectivePostoperative pleural empyema and bronchopleural fistula (BPF) remain devastating complications of anatomical lung resections, especially pneumonectomy. Open management of the residual pleural cavity via thoracostomy is a cornerstone of source control. Unlike prior reviews that discuss open window thoracostomy (OWT) mainly as salvage drainage, this work conceptualizes it as a structured staged strategy: source control, fistula management, physiologic optimization, and definitive reconstruction or planned permanent drainage. This review synthesizes current evidence on OWT as a staged intervention for post-resection empyema, integrating institutional and global literature.MethodsA narrative literature review searched PubMed, Cochrane Library, E-library and Google Scholar from 1983 to 2025 using the search terms “open window thoracostomy”, “Clagett procedure”, “postpneumonectomy empyema”, “bronchopleural fistula”, “chest wall reconstruction”, “thoracoplasty”, “intrathoracic vacuum therapy”, “muscle flap thoracostomy”. Thirty-four sources were selected for relevance to surgical management, reconstructive strategies, and outcomes.Key Content and FindingsPost-resection empyema is reported in 1–3% of anatomical lung resections, with mortality of 20–78% when complicated by BPF. OWT is an effective initial step, providing drainage and infection control. The procedure has moderate operative time and limited blood loss, making it applicable across a broad spectrum of severity. Pseudomonas aeruginosa predominates in postoperative empyema, underscoring the need for empiric anti-pseudomonal coverage. Open management duration varies considerably, governed not only by infection resolution but also by nutritional status, sarcopenia, and availability of adequate reconstructive tissue. Definitive closure of the thoracostomy window, achieved in a variable proportion of patients, often requires complex reconstruction with pedicled muscle flaps or omentum. Emerging adjuncts such as intrathoracic vacuum-assisted closure (VAC) and modified minimally invasive techniques show promise in expediting cavity sterilization and closure.ConclusionsOWT remains an effective, relatively safe index procedure for staged management of post-resection pleural empyema, particularly with BPF. Available evidence is heterogeneous and largely retrospective; no single technique is universally superior. Successful definitive closure depends on meticulous infection control, patient optimization, and well-vascularized reconstructive tissue. For patients with prohibitive comorbidities, OWT may serve as permanent therapy, offering durable stabilization. Future prospective studies with standardized outcomes are needed to move beyond expert opinion toward evidence-based standardization. Introduction Background Anatomical lung resection remains the cornerstone of curative treatment for both malignant and select infectious pulmonary diseases. Despite ongoing refinements in surgical technique and perioperative care, the development of pleural empyema and bronchopleural fistula (BPF) continues to represent a formidable challenge in thoracic surgery. Postoperative empyema has been reported with an incidence of 1–3% specifically after pneumonectomy (1-3). The clinical scenario is further complicated when empyema coexists with a BPF, a combination documented in up to 80% of cases (1). The reported incidence of BPF following lung resection varies widely, from 1% to 28%, with a notable predilection for right-sided resections (8–13%) compared to left-sided procedures (1–5%), a disparity largely attributed to differences in bronchial arterial supply and mediastinal coverage (3-5). Post-pneumonectomy complications warrant particular concern. Bronchial stump dehiscence in this setting carries the highest associated mortality, ranging from 20% to as high as 78% (6,7). Even after lesser resections, inadequate parenchymal sealing may result in a persistent air leak and subsequent development of a residual pleural space, with secondary infection occurring in approximately 2% of lobectomies (8). The management of these complications is inherently complex and often requires a multi-stage approach, as promptly emphasized by contemporary consensus guidelines (9). Rationale and knowledge gap The principal method of surgical source control for post-resection empyema is thoracostomy, which encompasses techniques ranging from the Eloesser flap to the Clagett procedure, collectively referred to as “open window thoracostomy” (OWT) in modern English literature (10). The historical evolution of pleural drainage, from Hippocrates’ initial descriptions of intercostal drainage to the 19th-century development of closed drainage systems and the subsequent introduction of plastic materials and the Heimlich valve, has established tube thoracostomy as a cornerstone of pleural disease management (11). However, for chronic or recurrent infections, particularly those associated with BPF, open drainage and window creation remain necessary to achieve adequate pleural debridement (10). In contrast to prior reviews and consensus statements that predominantly discuss OWT as a salvage drainage procedure, the present review uniquely conceptualizes it as a structured staged reconstructive and physiologic optimization strategy. OWT is here interpreted not as an isolated last‑resort measure, but as the first, deliberate step in a sequence that includes source control, BPF management, systemic patient preparation, and definitive reconstruction or, when reconstruction is not feasible, planned permanent drainage. Despite the established role of OWT, several areas of uncertainty persist. While contemporary guidelines from the American Association for Thoracic Surgery (AATS) and the European Association for Cardio-Thoracic Surgery (EACTS) strongly advocate for aggressive surgical drainage and the use of vascularized tissue for space obliteration, these recommendations are based largely on retrospective institutional series and expert consensus (Level of Evidence C) (9,12). The optimal timing of reconstructive intervention, the choice of reconstructive tissue, and the role of emerging adjuncts such as intrathoracic vacuum therapy remain subjects of ongoing investigation (13,14). Furthermore, definitive closure of the thoracostomy window, as originally conceptualized in the classic Clagett procedure, is not uniformly achievable, particularly in the setting of a persistent BPF (15). Although prior narrative reviews and consensus statements have summarized general management principles for postresection empyema and BPF, less attention has been directed toward conceptualizing OWT as a structured staged reconstructive and physiologic optimization strategy rather than solely a salvage drainage procedure. In addition, contemporary developments including intrathoracic vacuum assisted closure therapy, modified minimally invasive thoracostomy techniques, multidisciplinary perioperative optimization, and evolving reconstructive algorithms have not been comprehensively integrated into a unified practical framework. Therefore, the present review combines institutional experience with contemporary global literature to provide a clinically oriented synthesis of surgical strategies, reconstructive approaches, adjunctive therapies, and prognostic factors influencing definitive closure and long-term outcomes. Objective The aim of this narrative review is to provide a comprehensive synthesis of the current evidence on the role and clinical efficacy of OWT as a staged intervention for severe post-lung resection purulent complications. We integrate our institutional experience as illustrative contextual experience with contemporary global literature, examining surgical strategies, evolving techniques, and factors influencing definitive closure and long-term outcomes. The institutional data are not intended to constitute new independent clinical evidence. We present this article in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1417/rc). Methods A narrative review of the literature was performed to synthesize current evidence on the surgical management of post-resection pleural empyema with OWT. The search strategy is summarized in Table 1, in accordance with best practices for transparent reporting in narrative reviews. Table 1The search strategy summaryItemsSpecificationDate of searchApril 20, 2026Databases searchedPubMed, Cochrane Library, Google Scholar, E-library (Russian Science Citation Index)Search terms used“Open window thoracostomy”, “Clagett procedure”, “postpneumonectomy empyema”, “bronchopleural fistula”, “chest wall reconstruction”, “thoracoplasty”, “intrathoracic vacuum therapy”, “muscle flap thoracostomy”Timeframe1983–2025Inclusion and exclusion criteriaInclusion: all available studies written in English or Russian presenting patient data, including randomized controlled trials, prospective, retrospective, comparative studies, case series, and narrative/systematic reviews. Exclusion: non-English/non-Russian language studies, isolated case reports without generalizable findings, and papers without available full textSelection processLiterature review performed independently by three researchers (D.A.V., V.E.B. and A.I.G.). Discrepancies resolved by consensus with a third reviewer (A.A.P.)Any additional considerationsA total of 32 sources were selected for inclusion based on direct relevance to OWT techniques, management strategies, reconstructive options, and clinical outcomes in post-resection empyemaOWT, open window thoracostomy. The search strategy summary OWT, open window thoracostomy. Studies were prioritized based on their direct relevance to the surgical management of postresection empyema and BPF, with particular emphasis placed on reports describing OWT techniques, reconstructive strategies, management algorithms, and clinical outcomes. Preference was given to contemporary studies, larger institutional series, systematic reviews, and consensus statements, while landmark historical publications were retained to provide context regarding the evolution of thoracostomy techniques and staged management principles. Titles and abstracts were independently screened by two reviewers to assess relevance, followed by full text review of potentially eligible articles. In cases of overlapping datasets or duplicate institutional experiences, the most comprehensive or methodologically robust publication was prioritized. Discrepancies regarding study inclusion were resolved through discussion and consensus among the investigators. The institutional experience (n=11) presented in this review is included solely as contextual clinical illustration and is not reported with the detail required for independent clinical evidence; it is not intended to serve as a primary data source. Pleural empyema and BPF after lung resection: scope and significance of the problem In this paragraph summarizes the key published series of open-window thoracostomy/Clagett procedures, including the number of patients, BPF rate, closure/success rate, mortality, and the reconstructive techniques used (Table 2). Table 2Comparison of OWT/Clagett procedure seriesStudy [year]NBPF rate (%)Closure/success rate (%)Mortality (%)Reconstructive techniques and notesZaheer et al. [2006] (5)8465.5 (55/84)81 (permanent closure without recurrent infection)NRModified Clagett: debridement → obliteration with antibiotic solution. For BPF, bronchial stump closure reinforced with vascularized muscle flapShamji et al. [1983] (15)3177.4 (24/31)6.5 (permanent window closure)0 (empyema-/procedure-related)Clagett procedure (OWT → attempted closure with antibiotic). Persistent BPF prevented successful closureKuhtin et al. [2015] (14) (OWT subgroup)22 (of 39)82.1 (overall cohort)48.7 (antibiotic plombage), 5 patients—thoracoplasty35 (overall in-hospital for 39 patients)OWT + VAC therapy with sponge changes/gauze packing. Closure: antibiotic plombage, Alexander thoracoplastyMatsumiya et al. [2025] (16)42NR (absence of fistula was a favorable factor)47.6 (20/42)NROWT → closure: omentum [11], muscle flap [6], breast tissue [1], spontaneous [3], VAC [2]Bolaños-Morales et al. [2025] (17) (traditional OWT arm)32NRSurgical closure in 93 (13/14) of those closedNRTraditional OWT with rib resection, open packing, then surgical or spontaneous closureSeify et al. [2007] (18) (muscle flap reconstruction after OWT)55 (flaps in 42)NR (flaps also used for BPF closure)NR (aimed at obliteration)NRSerratus anterior, latissimus dorsi, pectoralis major, intercostal, rectus abdominis flaps, omentum. Mean 3 ribs resected prior to flapBPF, bronchopleural fistula; NR, not reported; OWT, open-window thoracostomy; VAC, vacuum-assisted closure. Comparison of OWT/Clagett procedure series BPF, bronchopleural fistula; NR, not reported; OWT, open-window thoracostomy; VAC, vacuum-assisted closure. Epidemiology and risk factors Pleural empyema is among the most devastating complications encountered in both thoracic surgical practice and the medical management of pneumonia (19,20). Postoperative empyema has been reported in 1–3% of cases following various intrathoracic procedures, with the highest incidence observed after pneumonectomy (1,2). In a contemporary series from our institution, postoperative empyema accounted for 57.1% of cases requiring OWT, slightly exceeding the proportion of post-pneumonic etiologies. The male predominance and median age in the sixth decade of life observed in our cohort mirror the epidemiologic profile of lung cancer, which constituted the primary indication for index surgery in the majority of cases (10). The prevalence of BPF among patients requiring thoracostomy is substantial. In our institutional experience, concomitant BPF was present in 81.8% (9 of 11) of patients undergoing OWT, consistent with literature reporting BPF in up to 80% of chronic empyema cases (1). Reported BPF rates vary substantially by extent of resection: approximately 0.1% after segmentectomy, 0.2–3% following lobectomy, and 0.9–6.8% after pneumonectomy, with some series documenting rates as high as 20% (4,5). Despite representing a broader spectrum of etiologies, the systematic review by Stüben et al. found that 63.6% of patients receiving intrathoracic vacuum therapy for empyema had a post-surgical etiology, underscoring the substantial burden of postoperative pleural space infections (13). Recognized risk factors for BPF development include a bronchial stump diameter exceeding 25 mm, excessive stump length, positive resection margin (R1), requirement for transfusion of four or more units of packed red blood cells, and technical difficulties encountered during bronchial closure (3). Right-sided resections are consistently identified as a significant risk factor, attributable to well-described anatomic vulnerabilities: the right main bronchus receives a solitary bronchial arterial supply, rendering it more susceptible to ischemic injury during mediastinal lymphadenectomy, and it lacks the protective coverage afforded to the left main bronchus by the aortic arch (3). In our series, the vast majority of OWT patients had undergone right-sided pneumonectomy, corroborating this anatomic predisposition. Key clinical points: ❖ Post-resection empyema complicates 1–3% of anatomical lung resections, with the highest risk after pneumonectomy. ❖ Post-resection empyema complicates 1–3% of anatomical lung resections, with the highest risk after pneumonectomy. ❖ BPF coexists in up to 80% of chronic empyema cases and dramatically increases mortality. ❖ BPF coexists in up to 80% of chronic empyema cases and dramatically increases mortality. ❖ Right-sided procedures, large stump diameter, and extended lymphadenectomy are consistent risk factors. ❖ Right-sided procedures, large stump diameter, and extended lymphadenectomy are consistent risk factors. Risk-prediction tools [e.g., Eurolung, Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD)] help identify patients who may benefit from prophylactic stump buttressing. Several risk prediction models have been developed to identify patients at heightened risk for postoperative complications. The Eurolung risk score and the STS GTSD risk calculator incorporate variables including male sex, body mass index, forced expiratory volume in one second (FEV1), and extent of resection to predict prolonged air leak and other complications (21). While these tools were not originally designed to predict empyema specifically, the identification of patients at high risk for any postoperative complication may facilitate targeted preventive strategies, including prophylactic buttressing of the bronchial stump. The role of bronchial stump buttressing in prevention The prophylactic reinforcement of the bronchial stump to prevent BPF remains a subject of ongoing debate in thoracic surgery. A systematic review by Skrzypczak et al. identified 16 studies examining the use of various buttressing tissues, with only one representing a randomized controlled trial (21). This trial, conducted by Sfyridis et al., demonstrated that intercostal muscle flap reinforcement in patients with diabetes mellitus undergoing pneumonectomy was associated with a significant reduction in BPF and empyema rates (22). Supporting evidence from large cohort studies has shown that the absence of bronchial stump coverage is an independent risk factor for BPF development, with an odds ratio of 1.65 (23). Various autologous tissues have been proposed for stump buttressing, including intercostal muscle flaps, pericardial fat pads, parietal pleura, mediastinal fat, diaphragmatic flaps, and omentum (21,22). The intercostal muscle flap remains the only technique validated in a randomized trial, and its robust vascular supply and proximity to the bronchial stump make it an attractive option (21). However, some authors have cautioned that improper harvesting technique may lead to iatrogenic ischemia of the intercostal muscle, paradoxically impairing stump healing (21). Novel methods of intraoperative perfusion assessment using indocyanine green fluorescence angiography or thermography have been proposed to mitigate this risk, although these remain investigational (21,22). Prophylactic coverage of the bronchial stump is particularly recommended in high-risk scenarios, including right-sided pneumonectomy, extended mediastinal lymphadenectomy, neoadjuvant chemoradiation, diabetes mellitus, and planned postoperative mechanical ventilation (9,21,24). Nevertheless, due to the absence of large-scale randomized data, a definitive consensus on the optimal tissue and technique for bronchial buttressing has yet to be reached (21). Clinical presentation and diagnosis The diagnosis of post-resection empyema requires a high index of suspicion. Clinical manifestations may range from insidious constitutional symptoms and low-grade fever in chronic presentations to acute sepsis with respiratory failure. The EACTS expert consensus statement emphasizes that early diagnosis and prompt intervention are critical to reducing morbidity and mortality (12). Computed tomography (CT) of the chest serves as the primary imaging modality for diagnostic evaluation. A systematic review and meta-analysis by Zettinig et al. identified five informative CT findings for the diagnosis of pleural empyema: pleural contrast enhancement, pleural thickening, loculation, increased attenuation of extrapleural fat, and subcostal fat stranding (25). The pooled sensitivity and specificity of these findings were 62% and 90%, respectively, with an area under the curve (AUC) of 0.80. Pleural enhancement and thickening were the most sensitive signs (84% and 68%, respectively), while fat stranding and extrapleural fat thickening were the most specific (91% and 97%, respectively) (25). Representing enhancement of both the visceral and parietal pleural layers, the “split pleura sign” has been described as a particularly characteristic finding of empyema (25). Ultrasonography of the chest has emerged as an invaluable bedside tool. Complicated parapneumonic effusions typically exhibit heterogeneous echogenicity, septations, or loculations on ultrasound, in contrast to simple effusions which tend to be anechoic (26). The sensitivity of ultrasound for detecting septations and debris within the pleural space, which may indicate the need for invasive intervention, is exceptional, and the modality offers the added benefit of being performed without ionizing radiation exposure (26). Magnetic resonance imaging, though less commonly employed, can differentiate transudates from exudates and evaluate extension into soft tissues, offering a potential alternative for select patients (26). In patients with suspected or confirmed BPF, fiberoptic bronchoscopy serves as an essential adjunctive diagnostic tool to definitively localize and characterize the fistulous tract. The AATS guidelines specifically recommend flexible bronchoscopy under local anesthesia in the semi-upright position to investigate for the presence of a fistula, emphasizing that a fistula should be assumed present until definitively excluded (9). For small or occult fistulae, adjunctive techniques such as ventilation scintigraphy or instillation of methylene blue into the bronchial stump may facilitate detection (27). Surgical strategies for source control: the role of OWT Building on the staged-strategy concept, the following sections detail the components of source control (OWT), fistula management, and definitive reconstruction. Principles and historical context The fundamental principle underlying the surgical management of post-resection empyema is the elimination of the infected pleural space. This is achieved through a sequential approach: adequate drainage and source control, followed by obliteration of the residual cavity and closure of any associated BPF. The surgical armamentarium for pleural empyema spans a spectrum from minimally invasive procedures to extensive open operations. The historical foundation of modern pleural drainage was laid by Hippocrates, who over two millennia ago described intercostal incision and insertion of metal tubes to drain thoracic pus, establishing the enduring principle that complete evacuation of the infected pleural space is essential for cure (11,18). The 19th century brought a major advance with the development of closed drainage systems incorporating water-seal mechanisms, which prevented the entry of atmospheric air into the pleural cavity and reduced the risk of secondary infection (11). The subsequent introduction of plastic materials and the Heimlich flutter valve in the 20th century further revolutionized chest tube design and ambulatory management (11). Within this evolutionary context, the open surgical management of chronic empyema gained prominence. The Eloesser flap, originally developed for tuberculous empyema, created a permanent, skin-lined pleurocutaneous fistula that allowed continual dependent drainage while preventing aspiration pneumonitis from the contralateral lung. The Clagett procedure, introduced by Oscar Theron “Jim” Clagett in 1963, refined this concept into a staged approach: the first stage involved creation of an OWT for dependent drainage and repeated packing changes; the second stage, performed once the cavity was clean and granulating, entailed closure of the chest wall with obliteration of the pleural space using antibiotic solution (10,28). This paradigm of staged management has remained the cornerstone of treatment for post-resection empyema for over six decades. OWT: technique and contemporary indications The technique of OWT employed in our institution entails resection of the lateral segments of two adjacent ribs to facilitate adequate debridement of the infected pleural space and achieve initial inflammatory control. This bone-plastic approach allows for the creation of a sufficiently large window that permits dependent drainage, daily cavity inspection, and atraumatic packing changes. The adequacy of window construction is of paramount importance. In our experience, three patients had previously undergone thoracostomy at outside institutions but required revision due to inadequate window dimensions that precluded proper drainage and wound care. This underscores the technical imperative of creating a sufficiently large window. Such a window typically requires resection of two to three rib segments over a length of 6–8 cm to ensure adequate dependent drainage and to prevent premature closure of the stoma before the pleural cavity has been sterilized (9,15). The indications for OWT in contemporary practice have been refined. While minimally invasive approaches such as video-assisted thoracoscopic surgery (VATS) decortication have proven highly effective for early-stage empyema (stage I and early stage II), chronic or recurrent infections with established peels, loculations, or associated BPF frequently necessitate open drainage (10,12). The EACTS consensus statement emphasizes that VATS debridement is most appropriate for empyema without BPF, while the presence of a fistula significantly increases the likelihood of requiring open techniques (12). In the landmark series by Shamji et al., OWT was performed in 31 patients with postpneumonectomy empyema, and the procedure was deemed to provide “adequate drainage and an excellent interim or permanent treatment of the infected pneumonectomy space” (15). A modified, less invasive approach to thoracostomy has been described by Bolaños-Morales et al., involving resection of only 4 cm of a single rib, with the wound edges protected by an Alexis wound retractor (17). In a retrospective cohort study comparing this modified technique (n=26) with conventional thoracostomy (n=32), the modified approach was associated with significantly shorter operative time (62 vs. 121 minutes), less blood loss (78 vs. 245 mL), and reduced hospital stay (9 vs. 40 days) (17). Furthermore, spontaneous closure of the window occurred exclusively in the modified technique group (10 of 10 closures in that group vs. 1 of 14 closures in the conventional group), suggesting that minimizing tissue trauma may facilitate eventual spontaneous obliteration of the pleural cavity (17). These findings, while preliminary, indicate that technical refinements to the classical OWT may improve perioperative outcomes without compromising source control. Adjunctive therapies: vacuum-assisted closure (VAC) The application of negative pressure wound therapy to the pleural cavity (intrathoracic VAC therapy) has emerged as a promising adjunct to OWT. A systematic review by Stüben et al. identified 14 studies encompassing 165 patients treated with intrathoracic vacuum therapy for pleural empyema (13). In 71.5% of cases, VAC therapy was applied following OWT. Treatment success rates ranged from 66.7% to 100%, with generally low complication rates. The duration of VAC therapy ranged from 6 to 120 days, with most authors employing negative pressures of 75–125 mmHg and sponge changes every 2–7 days (13). The literature distinguishes three principal modalities of intrathoracic vacuum therapy. Traditional VAC therapy employs polyurethane foam sponges placed through the OWT into the empyema cavity. Mini-VAC therapy, as described by Hofmann et al., utilizes a protective Alexis wound retractor sheath for sponge placement, obviating the need for extensive rib resection (13,29). Instillation-VAC therapy combines conventional negative pressure therapy with automated, controlled instillation of antiseptic solutions for cavity irrigation and bacterial load reduction (13). Several theoretical and practical advantages of VAC therapy have been identified. The mechanical effects of negative pressure promote wound granulation, reduce cavity size, and remove excess exudate. The ability to maintain the cavity in a sealed state between dressing changes minimizes disruption of respiratory mechanics, preserves patient mobility, and eliminates the need for painful daily packing changes on the ward—benefits that are particularly pronounced in the accelerated treatment protocol reported by Schneiter and colleagues (12,13). In a comparative cohort study, the duration of OWT was significantly shorter in patients receiving VAC therapy (39±17 days) compared to those managed with conventional packing (933±1,422 days) (12). Importantly, the published evidence base for intrathoracic VAC therapy remains limited to retrospective case series with inherent selection bias. As noted by Stüben et al., patients referred for VAC therapy frequently represent the most critically ill subset, with Karnofsky indices below 50% in the few studies reporting performance status, thereby limiting direct comparison with outcomes from conventional OWT series (13). Furthermore, the available literature is characterized by substantial heterogeneity in patient selection, empyema etiology, fistula status, VAC protocols, duration of therapy, and definitions of treatment success. Most studies originate from high volume specialized centers and involve relatively small cohorts, which further limits the generalizability of reported outcomes. The absence of prospective comparative trials and standardized treatment algorithms currently precludes definitive conclusions regarding the superiority of VAC therapy relative to conventional thoracostomy strategies. Accordingly, although intrathoracic VAC therapy appears to be a promising adjunct in the management of complex pleural space infections, its precise role within the contemporary surgical algorithm remains incompletely defined and warrants further prospective investigation. The authors of the systematic review appropriately call for prospective, randomized controlled trials comparing minimally invasive VAC therapy with VATS decortication for patients with pleural empyema (13). The EACTS consensus statement acknowledges that VAC therapy may serve as a useful adjunct to standard treatment, with the potential to reduce morbidity and hospital stay, but stops short of recommending it as a stand-alone modality (12). Key clinical points: ❖ Intrathoracic VAC therapy is a promising adjunct after OWT; success rates of 67–100% are reported, but evidence is limited to retrospective series. ❖ Intrathoracic VAC therapy is a promising adjunct after OWT; success rates of 67–100% are reported, but evidence is limited to retrospective series. ❖ Potential advantages include promotion of granulation, reduction of cavity size, and avoidance of painful daily packing changes. ❖ Potential advantages include promotion of granulation, reduction of cavity size, and avoidance of painful daily packing changes. Current data are insufficient to recommend VAC therapy as a stand‑alone replacement for conventional OWT; prospective comparative trials are needed. Microbiologic considerations and antimicrobial therapy The microbiologic profile of post-resection empyema warrants specific consideration. In our institutional experience, Pseudomonas aeruginosa was the predominant pathogen isolated from pleural fluid cultures, a finding characteristic of nosocomial infections and chronically colonized wounds in this patient population. The predominance of Gram-negative organisms, particularly Pseudomonas species, in post-surgical empyema contrasts with the microbiology of community-acquired pleural infections, where Streptococcus species and anaerobes are more frequently encountered (19). This distinction has important therapeutic implications, underscoring the necessity of empiric anti-pseudomonal coverage during the initial phase of treatment, guided by local antibiogram data and subsequently refined based on culture and sensitivity results. The evolution of pleural infection pathogens has been noted globally. Kwon observed that the causative organisms of pleural infection are changing and differ from those implicated in community-acquired pneumonia (19). The optimal duration of antibiotic therapy for pleural empyema remains an area of uncertainty, with no high-level evidence to guide clinical practice. The EACTS guidelines recommend continuation of antibiotics until clinical and laboratory signs of sepsis have resolved and drainage has ceased, typically for a minimum of 4–6 weeks in chronic empyema (12). Key clinical points: ❖ Pseudomonas aeruginosa predominates in post‑surgical empyema; empiric anti-pseudomonal coverage is essential. ❖ Pseudomonas aeruginosa predominates in post‑surgical empyema; empiric anti-pseudomonal coverage is essential. ❖ Antibiotic therapy should be guided by culture results and continued until clinical/laboratory resolution of sepsis, often ≥4–6 weeks. ❖ Antibiotic therapy should be guided by culture results and continued until clinical/laboratory resolution of sepsis, often ≥4–6 weeks. Management of the concomitant BPF Having achieved source control with OWT, the next critical step in the staged strategy is addressing the BPF—the principal barrier to definitive closure. Surgical principles The presence of a BPF fundamentally alters the surgical management of post-resection empyema and represents the principal obstacle to successful completion of the total Clagett procedure. In the seminal series by Shamji et al., permanent closure of the thoracostomy window was achieved in only 2 of 31 patients, with persistent or occult BPF identified as the primary cause of failure (15). The classic Clagett procedure in its original form did not adequately address the fistula, and subsequent modifications have incorporated techniques to identify, close, and reinforce the bronchial stump dehiscence. The AATS guidelines recommend an aggressive surgical approach entailing antibiotics, repeated debridement, closure of the chest wall defect when present, and obliteration of the residual pleural space using transposed vascularized tissue (9). During debridement of the empyema cavity, all efforts should be made to locate and close the open bronchus. Technical maneuvers to facilitate identification include filling the thoracic cavity with sterile saline and having the anesthesiologist ventilate the bronchial stump; the stream of air bubbles will guide the surgeon to the fistula site (9). However, even in BPFs occurring relatively early after pneumonectomy, locating the bronchial opening can be technically challenging due to rapid necrosis and distortion of the hilar structures. The principles of bronchial repair mirror those of BPF prevention: (I) minimize trauma to the bronchial end; (II) preserve blood supply up to the transected bronchial margin; (III) achieve meticulous apposition of the cut bronchial edges; and (IV) provide adequate reinforcement of the bronchial suture line with vascularized tissue (9). Because failure most commonly results from persistent or recurrent fistula, the original Clagett technique has been modified to include transposition of a well-vascularized muscle flap for closure and buttressing of the postpneumonectomy stump, thereby preventing further ischemia and necrosis (9). Muscle flap reconstruction Vascularized extrathoracic muscle flaps play a dual role in the management of BPF: they may facilitate direct closure of the fistula and serve to obliterate the residual pleural space. Commonly employed flaps include the latissimus dorsi, serratus anterior, pectoralis major, rectus abdominis, and intercostal muscles, with the selection depending on the location and volume of the space to be filled, as well as the availability of tissue following prior operations (10,18). The Emory experience reported by Seify et al. included 55 patients requiring muscle flap transposition for complex post-surgical empyema, with 51 procedures performed on 42 patients (18). The latissimus dorsi and serratus anterior were the most frequently utilized flaps. The authors concluded that the excellent blood supply of extrathoracic muscles and their ability to reach any location within the pleural cavity make them the ideal tissue for filling the infected pleural space (18). A narrative review by Kleeven et al. specifically addressed chest wall reconstruction after the Clagett procedure and other types of OWT, differentiating between pedicled flaps, free flaps, and VAC therapy (10). Pedicled flaps were identified as the preferred reconstructive option due to reliable vascularization, better tissue match, reduced scarring, and shorter operation time compared to free flaps. When pedicled flaps are unavailable, owing to damage during previous surgeries, insufficient volume for cavity obliteration, or prior use, free flaps may offer a viable alternative. The authors also note that VAC techniques have shown promise as an adjunct to surgical reconstruction (10). The optimal timing of muscle flap reconstruction remains a subject of clinical judgment. The EACTS consensus recommends that myoplasty should be performed under sterile conditions, as the failure rate can reach 25% in the presence of ongoing gross sepsis (12). This consideration informs the two-stage paradigm: the initial OWT achieves source control and cavity sterilization, while definitive reconstruction is deferred until the infection is adequately controlled and the patient is physiologically optimized. Key clinical points: ❖ Vascularized muscle flaps (latissimus dorsi, serratus anterior, etc.) serve dual purposes: fistula closure and cavity obliteration. ❖ Vascularized muscle flaps (latissimus dorsi, serratus anterior, etc.) serve dual purposes: fistula closure and cavity obliteration. ❖ Myoplasty should ideally be performed after infection is controlled; failure rates reach 25% in the presence of ongoing gross sepsis. ❖ Myoplasty should ideally be performed after infection is controlled; failure rates reach 25% in the presence of ongoing gross sepsis. When pedicled flaps are unavailable, free flaps or omentum may be considered. Accelerated and alternative protocols A notable refinement of the staged approach is the accelerated treatment protocol described by Schneiter et al., which was applied to 75 consecutive patients with postpneumonectomy empyema (12). This protocol involves open surgical debridement of the empyema space, followed by temporary closure of the chest with povidone-iodine-soaked dressings under negative pressure wound therapy, with dressing changes performed in the operating room every 2 days. Using this approach, all chest wall defects were definitively closed by direct suturing and/or muscle flap reinforcement within a median of 3 reoperations, with definitive thoracic closure achieved in 94.6% of patients within 8 days (12). The success rate was 86.7%, with a 90-day mortality of 1.3%. The advantages of this protocol include the avoidance of painful ward-based dressing changes, preservation of respiratory mechanics (since the chest is sealed between operations), maintenance of patient mobility and physiotherapy participation, and elimination of the need for patients to care for an open thoracic wound (12). For patients in whom open surgical management is contraindicated or unsuccessful, alternative strategies have been explored (30). Intrabronchial valves represent a novel, minimally invasive approach to BPF management. Leiter et al. reported the successful non-operative management of a postoperative empyema with BPF by placing an endobronchial valve to occlude the fistula, which then permitted safe administration of intrapleural fibrinolytics and antibiotics for definitive treatment of the empyema (29). Although the presence of a BPF is traditionally considered a contraindication to intrapleural fibrinolytic therapy due to the risk of spillage into the contralateral lung, the prior occlusion of the fistula with an endobronchial valve overcomes this limitation (29). Interventional bronchoscopic techniques for BPF closure have proliferated in recent years. Zhao reviewed the current landscape of interventional treatments, including the use of sealants, sclerosants, airway stents, occluder devices (such as atrial septal defect occluders), and autologous fat implantation (31). For small fistulae (<5 mm), bronchoscopic application of sealant or sclerosing agents may achieve closure. For larger defects (>5 mm), endobronchial valves, customized airway stents, and specially designed occluder devices offer promising results, although the published experience remains limited to case series and an absence of comparative effectiveness data (31). The development of 3D-printed, patient-specific airway stents and occluders represents an exciting frontier with the potential to further expand the applicability of minimally invasive BPF management (31). From open window to definitive closure: outcomes and prognostic factors The ultimate goal of the staged strategy is definitive closure; however, when reconstruction is contraindicated, permanent OWT constitutes a valid, durable therapeutic endpoint. Predictors of successful closure The identification of factors that predict successful closure of the OWT is of substantial clinical importance, as it enables preoperative counseling and informed decision-making. A recent single-center retrospective cohort study by Matsumiya et al. directly addressed this question in 42 patients with empyema managed with OWT (16). Closure was achieved in 20 patients (47.6%), employing omental filling (n=11), muscle flap filling (n=6), breast tissue filling (n=1), spontaneous closure (n=3), and VAC therapy (n=2). Strong predictors of successful closure included absence of malignancy (OR 2.68), absence of fistula (OR 3.41), age <70 years (OR 2.80), and hemoglobin ≥9.0 g/dL (OR 2.77), with performance status 0/1 emerging as the only statistically significant factor (OR 7.0, P=0.006) on logistic regression analysis (16). These findings align with our institutional experience, where the combination of BPF, malignancy, and poor performance status presented the greatest barrier to definitive closure. In the three patients in our series for whom thoracostomy was maintained as a permanent solution, the decision was driven by the burden of significant comorbidities that precluded safe reconstructive surgery. It is noteworthy that OWT can serve as a durable definitive treatment method in such circumstances, providing ongoing clinical stabilization and prevention of infectious recrudescence (15). The literature further acknowledges that spontaneous closure of an OWT is only feasible when the residual cavity has contracted substantially and infection has been fully eradicated; in the absence of these conditions, delayed reconstruction employing vascularized muscle or omental flaps remains necessary (1,10). The modified minimally invasive thoracostomy technique described by Bolaños-Morales et al., which was associated with exclusively spontaneous closure in their series, suggests that minimizing the size of the initial window may facilitate eventual spontaneous obliteration—an intriguing observation that merits further investigation (17). Long-term outcomes and quality of life The long-term outcomes of patients managed with OWT for post-resection empyema are intrinsically linked to the underlying disease process. The survival analysis by Di Giorgio et al. in 460 lung cancer resection patients with a minimum 10-year follow-up found that 38 patients (8.3%) developed postoperative empyema (32). Intriguingly, the 10-year survival rate was 23.7% in the empyema group vs. 15.9% in the control group without empyema—a difference that did not reach statistical significance after stratification by stage, histological type, and degree of lymphocytic infiltration of the primary tumor (32). The authors concluded that postoperative empyema does not appear to exert a significant independent prognostic effect on long-term survival in lung cancer patients, a finding that may provide some reassurance in the counseling of affected patients (32). For patients in whom the OWT cannot be closed and who must live with a permanent pleural stoma, the physical and psychological burden is considerable. The presence of a chronic, draining thoracic wound requires ongoing wound care, limits daily activities, and poses a risk of recrudescent infection. These considerations justify aggressive efforts at preoperative optimization, which includes nutritional supplementation, physical prehabilitation, and smoking cessation, to maximize the likelihood of achieving definitive closure (27). For the minority of patients in whom OWT remains permanent, comprehensive psychosocial support and meticulous wound care education are essential components of holistic management. Key clinical points: ❖ Successful closure depends on absence of BPF, younger age, good performance status, and adequate hemoglobin levels. ❖ Successful closure depends on absence of BPF, younger age, good performance status, and adequate hemoglobin levels. ❖ In patients with prohibitive comorbidities, permanent OWT provides durable stabilization and prevents infectious recrudescence. ❖ In patients with prohibitive comorbidities, permanent OWT provides durable stabilization and prevents infectious recrudescence. The physical and psychological burden of a permanent thoracic stoma justifies aggressive preoperative optimization to maximize the chance of closure. Table 3 summarizes the main clinical decision points for OWT in post-resection empyema: indications, differences by extent of resection, influence of BPF, role of VAC therapy, timing of closure, and acceptability of permanent OWT. Table 3Clinical decision-making framework for open window thoracostomy in post-resection empyemaClinical questionPractical guidanceRelevant sectionWhen should OWT be chosen over minimally invasive approaches?Chronic/recurrent empyema with thick peel, loculations, or suspected/confirmed BPF; failure of tube thoracostomy or VATS decorticationSection “Open window thoracostomy: technique and contemporary indications”How does management differ after pneumonectomy vs. lobectomy?Post-pneumonectomy empyema almost always requires OWT; after lobectomy, less extensive dead space may permit modified thoracostomy or earlier closure attemptsSections “Epidemiology and risk factors”, “Open window thoracostomy: technique and contemporary indications”, “Predictors of successful closure”How does the presence of BPF change the strategy?BPF is the main obstacle to closure; the strategy must include fistula identification, direct closure, and buttressing with vascularized tissue. OWT provides time for infection control before definitive fistula repairSection “Management of the concomitant bronchopleural fistula”When is intrathoracic VAC therapy useful?As an adjunct after OWT to promote granulation, reduce cavity size, and minimize painful packing changes. Not recommended as a stand-alone replacement for OWT outside of trialsSection “Adjunctive therapies: vacuum-assisted closure (VAC)”When should closure be attempted?After infection is controlled, the cavity is clean, BPF is addressed (or excluded), and the patient is nutritionally and physiologically optimized (performance status 0–1, Hb ≥9 g/dL)Section “Predictors of successful closure”When is permanent OWT acceptable?In patients with prohibitive comorbidities, poor performance status, incurable malignancy, or when adequate vascularized tissue is unavailable. Permanent OWT then serves as a durable palliative endpointSection “Long-term outcomes and quality of life”, ConclusionsBPF, bronchopleural fistula; Hb, hemoglobin; OWT, open-window thoracostomy; VAC, vacuum-assisted closure; VATS, video-assisted thoracoscopic surgery. Clinical decision-making framework for open window thoracostomy in post-resection empyema BPF, bronchopleural fistula; Hb, hemoglobin; OWT, open-window thoracostomy; VAC, vacuum-assisted closure; VATS, video-assisted thoracoscopic surgery. Strengths and limitations This narrative review possesses several strengths. It synthesizes evidence from a comprehensive range of sources spanning nearly four decades, encompassing landmark historical series, contemporary institutional reports, systematic reviews, and expert consensus guidelines. By integrating our institutional experience with the global literature, we provide both a broad overview of established principles and a granular perspective on real-world clinical challenges. The review addresses the full trajectory of care for patients with post-resection empyema, from preoperative risk stratification and prevention, through acute surgical management and staged reconstruction, to long-term outcomes and prognostic factors. Several limitations warrant acknowledgment. First, as a narrative review, the literature selection was not exhaustive, and the potential for selection bias exists; a systematic review methodology would have permitted a more rigorous synthesis of the evidence. Second, our institutional data are derived from a small, retrospective, single-center cohort (n=11), which limits the generalizability of our specific observations. Third, the evidence base informing the surgical management of post-resection empyema remains dominated by retrospective case series and expert opinion; The lack of randomized controlled trials in this field is understandable given the relative rarity and heterogeneity of the condition, and it precludes definitive, evidence-based recommendations on several key aspects of care. Fourth, most published studies have employed heterogeneous definitions of treatment success and variable follow-up durations, limiting the comparability of outcomes across series. Finally, the emerging literature on novel techniques, such as intrathoracic VAC therapy and modified minimally invasive thoracostomy, is insufficiently mature to permit firm conclusions regarding their role relative to established procedures. The narrative nature of this review means that the literature selection, while comprehensive, is not exhaustive and carries an inherent risk of selection bias. Conclusions Postoperative pleural empyema, particularly when complicated by BPF, remains one of the most challenging complications in thoracic surgical practice. The available evidence is heterogeneous, derived predominantly from retrospective institutional series, and no single surgical technique can be considered universally superior. OWT, in its various iterations from the classical Clagett procedure to modern modified techniques, constitutes an effective and safe index procedure in the staged surgical management of this complex condition. It is best understood not as an isolated salvage drainage procedure, but as the initial step in a structured strategy that integrates source control, fistula management, physiologic optimization, and definitive reconstruction or, when reconstruction is not feasible, planned permanent drainage. Definitive closure of the thoracostomy window is achievable in a substantial proportion of patients, contingent upon the resolution of infection, the successful management of any concomitant BPF, and the availability of well-vascularized reconstructive tissue. Successful closure is multifactorial, critically depending on BPF status, adequacy of infection control, patient performance status, nutritional reserve, availability of well-vascularized tissue, and institutional expertise. Pedicled muscle flaps, such as the latissimus dorsi and serratus anterior, represent the preferred reconstructive option, with free flaps and omentum serving as alternatives when pedicled tissue is unavailable or insufficient. Emerging adjuncts such as intrathoracic VAC therapy may contribute to expediting cavity sterilization and potentially enhancing the likelihood of successful closure, although their precise role awaits confirmation by prospective trials. The duration of the open management phase varies considerably and is governed not solely by microbiologic control of infection but also by the patient’s overall physiologic and functional status. Performance status, age, hemoglobin level, and the presence or absence of BPF and malignancy are key determinants of the probability of achieving definitive thoracostomy closure. This recognition justifies the implementation of aggressive multidisciplinary preoperative optimization strategies, encompassing nutritional support, physical prehabilitation, and management of comorbidities. For patients burdened by severe, prohibitive comorbid conditions in whom plastic reconstruction is contraindicated, OWT may serve as a definitive therapeutic endpoint, affording durable clinical stabilization and prevention of life-threatening infectious recrudescence. In all cases, the treatment paradigm must be individualized, balancing the goals of source control, cavity obliteration, and fistula closure against the patient’s overall physiologic reserve and long-term prognosis. Future research priorities should include multicenter prospective cohort studies with standardized outcome definitions and extended follow-up. The establishment of standardized outcome reporting frameworks and multicenter registries would facilitate more robust comparative effectiveness analyses. Randomized trials comparing intrathoracic VAC therapy, conventional thoracostomy strategies, and different reconstructive techniques are urgently needed to move the field beyond expert opinion toward evidence-based standardization of care. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1417/prf